Drugs in development with potential to be first-in-class in 2016, by therapeutic area
This statistic shows the share of drugs in clinical development and regulatory review that have the potential to be first-in-class as of 2016, by therapeutic area. Some 86 percent of Alzheimer's disease drugs in clinical development had the potential to be first-in-class, as of 2016.